GSA Capital Partners’s Adaptive Biotechnologies ADPT Stock Holding History

GSA Capital Partners’s Portfolio ADPT Stock Details ADPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$826K	Buy	+38,500	New	+$590K	0.05%	632
2024 Q4	–	Sell	-48,165	Closed	-$247K	–	1565
2024 Q3	$247K	Buy	+48,165	New	+$210K	0.02%	1324
2023 Q2	–	Sell	-133,396	Closed	-$1.18M	–	1467
2023 Q1	$1.18M	Buy	133,396 +42,793	+47%	+$377K	0.12%	238
2022 Q4	$692K	Buy	90,603 +61,901	+216%	+$482K	0.09%	407
2022 Q3	$204K	Buy	28,702 +4,457	+18%	+$42K	0.03%	1216
2022 Q2	$196K	Buy	+24,245	New	+$213K	0.03%	1074
2022 Q1	–	Sell	-7,485	Closed	-$210K	–	1365
2021 Q4	$210K	Buy	+7,485	New	+$229K	0.03%	1182
2019 Q3	–	Sell	-6,000	Closed	-$290K	–	1357
2019 Q2	$290K	Buy	+6,000	New	+$266K	0.03%	1021

Other funds holding ADPT

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

GSA Capital Partners's ADPT Position: Q2 2026 in Review

GSA Capital Partners opened a new position in Adaptive Biotechnologies (ADPT) in Q2 2026: 38,500 shares worth $826K. The stake represents 0.05% of the portfolio and ranks #632 among its holdings. This is a return to the name: GSA Capital Partners previously reported a position in ADPT as recently as Q3 2024.

GSA Capital Partners first reported a position in ADPT in Q2 2019 and has held it in 8 quarters since. The position peaked at $1.18M in Q1 2023. 300 funds tracked by Wall St. Rank hold ADPT as of Q2 2026.

GSA Capital Partners held 38,500 shares of Adaptive Biotechnologies worth $826K as of Q2 2026.
Adaptive Biotechnologies was a new GSA Capital Partners position in Q2 2026.
Adaptive Biotechnologies made up 0.05% of GSA Capital Partners's portfolio in Q2 2026, its #632 holding.
GSA Capital Partners first reported a position in Adaptive Biotechnologies in Q2 2019 and has held it in 8 quarters since.
GSA Capital Partners's Adaptive Biotechnologies position peaked at $1.18M in Q1 2023.
300 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.